Motivation 2 Quit (M2Q): Tobacco Cessation on Prescription – an effective treatment?
More details
Hide details
Karolinska Institutet, Stockholm, Sweden
The Public Health Agency, Stockholm, Sweden
The Swedish Institute for Health Economics, Lund, Sweden
University of Gothenburg, Gothenburg, Sweden
Tanja Tomson   

Karolinska Institutet, Stockholm, Sweden
Publication date: 2023-04-25
Tob. Prev. Cessation 2023;9(Supplement):A52
To prevent the harmful effects of tobacco use and related inequalities in health, clinical guidelines for tobacco cessation have been developed. Primary healthcare (PHC) has an important role in providing tobacco cessation treatment since it has the main responsibility for health promotion in the Swedish healthcare system and most of the population has regular contact with PHC. Individuals from lower socioeconomic groups also visit PHC more often than those from higher socioeconomic groups. However, socioeconomically disadvantaged groups appear to face specific challenges in quitting their tobacco use and PHC providers have reported several barriers to work with tobacco cessation. In previous qualitative studies, Tobacco Cessation on Prescription, (TCP) is perceived as a useful tool that could facilitate a more structured and effective approach to tobacco cessation compared to current practices targeting socioeconomically disadvantaged groups in PHC. Findings also suggest that TCP may have an impact on patient and PHC provider behaviour, leading to decreased tobacco use among patients but this has previously not been evaluated. Therefore, we evaluated the effectiveness of TCP compared to standard treatment in socioeconomically disadvantaged areas in Swedish primary healthcare.

Material and Methods:
A pragmatic cluster randomized controlled trial, in 18 PHC centres in socioeconomically disadvantaged areas in Stockholm. Randomization was conducted at the PHC centre level using a computergenerated random allocation sequence.

Intervention group (n = 8) and control group (n = 10). At the PHC centres, 250 patients (TCP n = 188, standard treatment n = 62) were recruited. There was a statistically significant effect of TCP compared to standard treatment for the outcomes 7-day abstinence at 6 months (OR adjusted 5.4, 95% CI 1.57 to 18.93) and 3-month continued abstinence at 6 (OR adjusted 6.4, 95% CI 1.30 to 31.27) and 12 months follow-up (OR adjusted 7.8, 95% CI 1.25 to 48.82).

This first study evaluating the effectiveness of TCP suggests that it may be effective in achieving abstinence from tobacco use compared to standard treatment in vulnerable populations.

The authors have declared that no competing interests exist.
Leppänen A, Biermann O, Sundberg CJ, Tomson T. Perceived feasibility of a primary care intervention for Tobacco Cessation on Prescription targeting disadvantaged groups in Sweden: a qualitative study. BMC Research Notes 2016;9(1):151. https://bmcresnotes.biomedcent....
Leppänen A, Lindgren P, Sundberg CJ, Petzold M, Tomson T. A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study. JMIR Res Protoc 2016;5(3):e188. https://www.researchprotocols.....
Leppänen A, Ekblad S, Tomson T. Tobacco Cessation on Prescription as a primary health care intervention targeting a context with socioeconomically disadvantaged groups in Sweden: A qualitative study of perceived implementation barriers and facilitators among providers. PLoS ONE 14(2): e0212641. id=10.1371/journal.pone.0212641.
Leppänen A, Ekblad S, Tomson T. Experiences of tobacco cessation including a prescription approach among patients in Swedish primary health care with a focus on socioeconomically disadvantaged areas. PLoS ONE, 2020; 15(10):
Motivation 2 Quit (M2Q): A cluster randomized controlled trial evaluating the effectiveness of Tobacco Cessation on Prescription in Swedish primary healthcare – PLoS ONE, 2022,